Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 26271-26280 Newer>

The Motley Fool September 25, 2007 Brian Lawler	Amgen's European Adventures The European Medicines Agency announces that it has reversed its decision on Amgen's cancer drug Vectibix, allowing it on the market for a limited patient population. Investors, take note.
The Motley Fool September 25, 2007 Seth Jayson	The Easiest Money in the Market These foreign stocks have showed amazing gains since the market's big drop five weeks ago: LDK Solar... Aluminum Corp. of China... Sinopec Shanghai Petrochemical... Companhia Vale do Rio Doce...Vimpel-Communications...
The Motley Fool September 25, 2007 T. Hanson & B. Richards	Don't Sell Without Reading This First For a short-term capital gain, a stock held for less than one year, the tax man takes up to 35%. For a long-term capital gain, a stock held longer than one year, the government takes between 5% and 15%. Investors, think through the consequences of your sell decision.
The Motley Fool September 25, 2007 Mike Kasprzyk	Quick Take: Goldman Sachs' Lending Hand The London Treasury seeks advice from Goldman Sachs for its struggling UK bank Northern Rock, reflecting confidence in the U.S. investment bank's uniquely strong brand and history of proven results.
The Motley Fool September 25, 2007 Rick Aristotle Munarriz	EchoStar Gets Into the Sling of Things Satellite provider EchoStar is buying the maker of the popular Slingbox while pondering a move to split into two separate companies. Investors, take note.
The Motley Fool September 25, 2007 Jeremy MacNealy	Fool on Call: Ni Hao, Best Buy! Best Buy's Q2 conference call offers important insight into the gains and growing pains of its operations in China.
The Motley Fool September 25, 2007 Matt Koppenheffer	TJ's Crafty Settlement TJX's settlement for a security breach could reel customers into its stores with vouchers and future events.
The Motley Fool September 25, 2007 Brian Orelli	Onyx Moves Ahead Bayer and Onyx score a positive recommendation from an EU committee, moving one step closer to being able to market their cancer-fighting drug Nexavar in Europe.
The Motley Fool September 25, 2007 Rich Smith	Is Steelcase's Strength in Positive Thinking? Comparing recent earnings reports from office furniture manufacturers Steelcase and Herman Miller show two very different industry outlooks.
Wall Street & Technology September 11, 2007 Larry Tabb	The Boston Equity Exchange (BEX) Calls It Quits It was the first of the regional exchanges (dealer-capitalized or not) to throw in the towel. But what does this mean? Is the Boston Stock Exchange dead? Is it valueless?
<Older 26271-26280 Newer> Return to current articles.